Advanced NanoTherapies announced that it closed an oversubscribed Series B financing worth more than $31 million. An undisclosed strategic investor, along with S3 Ventures, co-led the round. The T45 Fund and new and existing investors also participated. Funding adds to $4 million raised in 2023. The funds support the company's therapies for … [Read more...] about Advanced NanoTherapies raises $31M for drug-coated balloon tech
Technologies & Devices
Johnson & Johnson CMO explains advances behind ‘game-changer’ Shockwave C2 Aero catheter
With its $13 billion acquisition of Shockwave Medical in 2024, Johnson & Johnson added the market leader in intravascular lithotripsy (IVL) to its portfolio. Since then, the company has continued to build on that leadership position with new product rollouts. That includes the recent launch of Shockwave C2 Aero, the latest catheter system … [Read more...] about Johnson & Johnson CMO explains advances behind ‘game-changer’ Shockwave C2 Aero catheter
Olympus to acquire urologic balloon spacer maker BioProtect for $270M
Olympus announced today that it entered into a definitive agreement to acquire urologic medical device manufacturer BioProtect. The deal includes a value of $270 million, with certain amounts held in escrow for a period dependent on uninterrupted business operation. Tokyo-based Olympus expects to complete the deal by the end of the second … [Read more...] about Olympus to acquire urologic balloon spacer maker BioProtect for $270M
Adagio submits ventricular ablation system to FDA
Adagio Medical (Nasdaq:ADGM) announced today that it submitted its premarket approval (PMA) application to the FDA for its vCLAS system. The company submitted its vCLAS ventricular ablation system for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia (VT) in patients with ischemic or non-ischemic … [Read more...] about Adagio submits ventricular ablation system to FDA
Reflow Medical has positive data for coronary drug-eluting stent
Reflow Medical today announced the first six-month clinical results from a study of its Spur Elute sirolimus-eluting retrievable stent system. San Clemente, California-based Reflow designed its stent system to transfer a proprietary drug formulation to the diseased lesion without leaving a permanent metallic implant behind. The device’s … [Read more...] about Reflow Medical has positive data for coronary drug-eluting stent
Endologix acquires Pounce thrombectomy system from Surmodics
Endologix announced today that it acquired the Pounce thrombectomy system from Surmodics, closing the deal on May 18. Pounce, an FDA-cleared and commercially available fully mechanical thrombectomy platform, offers the non-surgical removal of thrombi and emboli from peripheral arteries. It comes in multiple configurations to support use across a … [Read more...] about Endologix acquires Pounce thrombectomy system from Surmodics
Cagent Vascular reports first-in-human IVL cases, closes $41M Series D
Cagent Vascular today announced the first-in-human cases with its Serranator Sonic IVL system alongside significant funding. In addition to the first human use of the intravascular lithotripsy (IVL) system, the company closed a $41 million Series D round. Serranator Sonic IVL's first human procedures took place in Uzbekistan as part of its … [Read more...] about Cagent Vascular reports first-in-human IVL cases, closes $41M Series D
Elixir Medical study backs DynamX bioadaptor against drug-eluting stent
Elixir Medical today announced four-year results from a study comparing its DynamX coronary bioadaptor system to a leading drug-eluting stent (DES). The BIOADAPTOR randomized controlled trial compared DynamX to the Medtronic Resolute Onyx DES, the current standard of care. It compared the therapies across Japan, Europe and New Zealand. … [Read more...] about Elixir Medical study backs DynamX bioadaptor against drug-eluting stent
Boston Scientific study of Seismiq coronary IVL meets endpoints
Boston Scientific (NYSE:BSX) today reported positive results from the FRACTURE study of its Seismiq intravascular lithotripsy (IVL) catheter. The pivotal FDA investigational device exemption (IDE) trial evaluates the use of the Seismiq 4CE coronary IVL catheter in the treatment of patients with severely calcified coronary artery disease … [Read more...] about Boston Scientific study of Seismiq coronary IVL meets endpoints
Stryker enrolls first patient in first-in-human study of AVS IVL in a coronary indication
Amplitude Vascular Systems (AVS), now part of Stryker (NYSE:SYK), today announced the first patient enrolled in a new study of its IVL technology. Stryker completed its acquisition of AVS, worth up to $835 million, earlier this month. The company develops intravascular lithotripsy (IVL) technology for treating severely calcified arterial … [Read more...] about Stryker enrolls first patient in first-in-human study of AVS IVL in a coronary indication
